Viatris Inc is a global healthcare company that focuses on providing access to medicines, including generic and specialty pharmaceuticals, to improve patient health outcomes worldwide. Formed from the merger of Mylan and Upjohn, a division of Pfizer, Viatris leverages its extensive portfolio to develop and manufacture a wide range of high-quality medications that address diverse therapeutic areas. With a commitment to sustainability and innovation, the company emphasizes collaboration with healthcare providers, policymakers, and communities to enhance the accessibility and affordability of essential healthcare solutions for patients around the globe. Read More
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
The firm increased its full-year adjusted EPS guidance to $2.16 to $2.30 from its previous guidance of $2.12 to $2.26, including the impact of share repurchases.
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
NEW ORLEANS, May 08, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company’s securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvania.
Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.50 per share was in line with analysts’ consensus estimates.
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Solaris Energy Infrastructure, Inc. (NYSE: SEI), Viatris Inc. (NASDAQ: VTRS), Bakkt Holdings, Inc. (NYSE:BKKT), and Cerevel Therapeutics Holdings, Inc. (CERE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET.
NEW YORK and NEW ORLEANS, May 06, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company’s securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvania.
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a complaint has been filed in the United States District Court for the Western District of Pennsylvania on behalf of investors who purchased or acquired the securities of Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) between August 8, 2024 and February 26, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers (the “Complaint”).
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
NEW ORLEANS, May 01, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company’s securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvania.
NEW YORK and NEW ORLEANS, April 29, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company’s securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvania.
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
